In 1997, doctors in England received official guidelines on the use of statins (3-hydroxy-3-methylglutaryl coenzyme A inhibitors) for primary and secondary prevention of coronary heart disease (CHD). Six months later we determined the status of patients who had been discharged from a specialist lipid clinic in 1989. 195 patients received questionnaires, with the consent of their general practitioners, regarding morbidity in the subsequent decade and present medication, and were asked to have their cholesterol checked. Analysis was confined to the 86 with a current cholesterol measurement.
INTRODUCTION
The advent in 1989 of statins (3-hydroxy-3-methylglutaryl coenzyme A inhibitors) gave clinicians a powerful means of reducing low-density-lipoprotein cholesterol. Previous experience with hypolipidaemic agents for prevention of coronary heart disease (CHD) had been disappointing, and at first the statins were viewed with suspicion. Today, however, there is solid evidence for their value in both secondary and primary prevention of ischaemic heart disease. The groundbreaking 4S studyl, assessing simvastatin therapy in patients with pre-existing CHD, showed a 42% reduction in risk of coronary death; and subsequently the LIPID trial2'3 yielded a reduction not only in CHD mortality but also in overall mortality. In primary prevention, the first major report was from the WOSCOPS4 trial, targeted to individuals with a 1.5% or greater risk of myocardial infarction or CHD death per year. This and later trials indicate that, whatever the original risk, treatment with statins can reduce it by onethird; consequently, the debate has switched to costeffectiveness. Ramsay and co-workers5'6 suggested that these expensive agents should be used only in people whose risk was 3% per year or more (twice that in WOSCOPS), and provided tables (the Sheffield tables) whereby the risk could be calculated. In the UK, the Standing Medical Advisory Committee opted for the 3% figure and the Chief Medical Officer for England advised doctors accordingly7 (Box 1). At our hospital a special lipid clinic existed until 1986, when it was closed. We were curious to see how the advent of statins had affected the treatment of patients who had subsequently been managed in general practice. We conducted an inquiry in 1998, six months after the Chief Medical Officer issued his recommendations.
METHODS
With the consent of their general practitioners, 195 patients who had been discharged from the lipid clinic before November 1989 were asked to complete a questionnaire with simple yes/no responses regarding angina, heart attacks, coronary artery surgery, stroke, diabetes mellitus, high blood pressure and smoking since 1989. They were also provided with a list of all past and present treatments for hyperlipidaemia, including trade names, and were asked to indicate any that they were currently receiving. Finally, they were requested to attend their general practitioner or 
Secondary prevention
Statins should be prescribed to those who have had a heart attack and have total cholesterol of 4.8 mmol/L or more, or have angina and total cholesterol of 5.5 mmol/L or more
Statin dosage
As necessary to reduce total cholesterol to 5 mmol/L or by 20-25% the hospital for a fasting cholesterol measurement. Our own database contained information on the patients' cholesterol, medication and diagnosis at the time of discharge from the clinic.
RESULTS
This analysis is confined to the 86 patients (out of 195) who completed the questionnaires and had their cholesterol measured.
Primary prevention 61 patients were on dietary and/or pharmacological regimens for primary prevention of CHD at the time of discharge from the lipid clinic in 1989; 14 were now receiving statins. According to the Chief Medical Officer's advice, none of the 61 required statins.
Secondary prevention 25 patients were receiving treatment for secondary prevention in 1989. In 1998, 14 were receiving a statin but in 8 of these the recommended reduction in cholesterol had not been achieved. One was still receiving a hypolipidaemic drug other than a statin, and 10 were not being treated. In other words, 19 (76%) of 25 were not receiving adequate treatment.
DISCUSSION
Over the past 20 years, there has been a strong drive to shift the responsibility for patient follow-up from secondary care to the primary care setting. This places a large burden on general practitioners when 'evidence-based medicine' demands changes in management; the results of this survey indicate that a high proportion of patients were not receiving the recommended therapy. It must be said, however, that the survey was conducted only six months after publication of the recommendations; moreover, there are reasons why the general practitioners might have chosen to ignore them. In primary prevention, if one follows the Sheffield tables, the threshold for treatment of hyperlipidaemia has actually increased over the past decade; thus, many patients who were on hypolipidaemic therapy when discharged from the lipid clinic would not today be candidates for treatment. One reason why general practitioners did not take them off treatment may have been that the patients perceived that even a small reduction of CHD risk was worthwhile; the 3% Sheffield threshold is not generous. Another reason, of course, is that the practices may have continued to issue prescriptions without reviewing their prescribing policies.
How might we ensure that, in future, hyperlipidaemic patients benefit promptly from advances in evidence-based medicine? A possible solution might be something akin to the Tayside Thyroid Register (Professor R T Jung, Ninewells Hospital, Dundee), whereby patients have blood tests at predetermined intervals; the results are reviewed by a specialist who then advises the general practitioner. But hyperlipidaemic patients are only a minute proportion of those at risk of death and disability from CHD. A central hyperlipidaemia register would not help in the much larger secondary-prevention group, since most of those requiring statins do not have a very high cholesterol. The most striking finding in our survey was that 76% of patients eligible for statins were not receiving these drugs. It echoes studies such as ASPIRE8, which have shown that treatments effective in secondary prevention are grossly under-used. A systematic and coordinated approach to secondary prevention would be preferable to strategies that concentrate on single risk factors.
The London Fever Hospital: from pesthouse to posh pad The London Fever Hospital in Liverpool Road, Islington, was built in 1848 to a design by Charles Fowler. A Palladian building with late classical features, it resembled a country mansion. The similarity between hospitals of the period and domestic structures extended beyond bricks and mortar to terms used for members of the staff. 'House' governors are no more but house physicians and surgeons continue, in contrast to interns in hospitals in the USA. Though funds for the new hospital were available from money paid by the Great Northern Railway Company in compensation for the demolition of the former fever hospital to make way for the construction of King's Cross Station, protests against building a 'deadly pesthouse' in a populated area took some time to overcome. After serving as a fever hospital for over a century, the hospital became the maternity branch of the Royal Free Hospital until, in recent years, the building was sold to private developers and converted to an attractive residential project now named Old Royal Free Place.
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